2023 Fiscal Year Final Research Report
Clinicopathological and moleclar biological study of renal cell carcinoma of novel and rare histologca types
| Project/Area Number |
21K06914
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 49020:Human pathology-related
|
|---|
| Research Institution | Tokyo Women's Medical University |
|---|
Principal Investigator |
Nagashima Yoji 東京女子医科大学, 医学部, 教授 (10217995)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
加藤 生真 横浜市立大学, 医学部, 助教 (80644939)
近藤 恒徳 東京女子医科大学, 医学部, 教授 (50301544)
|
|---|
| Project Period (FY) |
2021-04-01 – 2024-03-31
|
| Keywords | Renal cellcarcinoma / Pathology / TFE3-rearranged RCC / FH-deficient RCC / ACD-associated RCC / Immunohistochemistry / Break apart FISH / Diagnosstic algorithm |
|---|
| Outline of Final Research Achievements |
Pathological classification of renal cell carcinoma (RCC) contains various histological and genetic types. This research aimed to reveal clinicopathological features. The cases examined were RCCs surgically resected at the Tokyo Women's Medical University Hospital and subjected for pathological consultation to the PI. We revealed the facts as follows; ①TFE3-rearranged RCC occurs not only in younger population but also in elder population and in patients receiving long-term diaysis, ②Although fumarate hydratase-deficient RCC presents morphological overlapping with papilary RCC, precise differential diagnosis is required, considering unfavorable prognoses and possibility of a hereditary background. ③Acquired cystic disease-associated RCC possesses similar methylation profile with papillary RCC. ⑤Additionally, algorithm for histopathological diagnosis of RCCs mainly based on immunohistochemistry.
|
| Free Research Field |
人体病理学
|
| Academic Significance and Societal Importance of the Research Achievements |
2023年に出版されたWHO腎細胞癌分類では新規組織型、特に分子生物学的に定義される組織型が導入され、本邦で用いられている腎癌取扱い規約(第5版、2020年出版）との間にギャップが生じている。本研究では新たに導入された新規組織型の性質を明らかにすることができた。また、分子生物学的手法の使用に制約のある施設であっても、ルチーン化されていｒ免疫染色を用いて、正確な診断が可能となるアルゴリズムを確立することができた。これらを通じて腎細胞癌の稀少組織型を集積し、大規模な臨床病理学的検討への進展が期待される。
|
